23 related articles for article (PubMed ID: 38687926)
1. A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma.
Buchbinder EI; Cohen JV; Tarantino G; Lian CG; Liu D; Haq R; Hodi FS; Lawrence DP; Giobbie-Hurder A; Knoerzer D; Sullivan RJ
Cancer Res Commun; 2024 May; 4(5):1321-1327. PubMed ID: 38683104
[TBL] [Abstract][Full Text] [Related]
2. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).
Germann UA; Furey BF; Markland W; Hoover RR; Aronov AM; Roix JJ; Hale M; Boucher DM; Sorrell DA; Martinez-Botella G; Fitzgibbon M; Shapiro P; Wick MJ; Samadani R; Meshaw K; Groover A; DeCrescenzo G; Namchuk M; Emery CM; Saha S; Welsch DJ
Mol Cancer Ther; 2017 Nov; 16(11):2351-2363. PubMed ID: 28939558
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
4. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
5. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
6. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
9. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Sáez JM
Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
[TBL] [Abstract][Full Text] [Related]
10. Role of BRAF in thyroid oncogenesis.
Caronia LM; Phay JE; Shah MH
Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]